Axial Therapeutics, Inc.

Axial Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel gut-targeted therapies for neurological disorders. Their mission is to revolutionize the treatment of diseases like autism and Parkinson's by harnessing the power of the gut microbiome, a relatively unexplored area of drug discovery. They have a unique approach that targets the gut-brain axis, believing that by understanding the interactions between the gut microbiome and the brain, they can develop treatments that address the underlying pathology and symptoms of these conditions.

Axial's lead product candidate, AB-2004, is currently in Phase 2b clinical trials for the treatment of irritability associated with autism. They are also developing AX-5006 for Parkinson's Disease, with a clinical trial planned to begin in 2024. Axial is committed to developing innovative, safe, and effective treatments for patients with neurological disorders and conditions, and they are at the forefront of research in this exciting new field.

Axial Therapeutics offers competitive salaries and a comprehensive benefits package to its employees. While specific details are not outlined on the website, the company states that it provides a "comprehensive array of benefits" to its team members. This likely includes standard offerings such as health insurance, dental and vision coverage, paid time off, retirement plans, and possibly additional perks such as life insurance, disability coverage, and employee assistance programs.

Axial Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and conditions by harnessing the power of the microbiome-gut-brain axis. They are developing small molecule drugs with defined mechanisms of action that act on new targets in the gut to mitigate the impact of metabolites and bacteria linked to neurological diseases and disorders. Their lead programs are focused on Autism Spectrum Disorder and Parkinson's disease, and they are also pursuing preclinical discovery of gut-targeted therapies in oncology and NASH/fibrosis.

Axial Therapeutics fosters a dynamic and collaborative work environment built around a shared mission to revolutionize medicine through microbiome research. They prioritize a culture of teamwork and innovation, valuing diversity of experience and expertise while ensuring a safe and secure environment for all employees. Their commitment to making a difference in the lives of patients with serious diseases drives their efforts and creates a passionate and dedicated team.